Formulation Development and Characterization of Darunavir and Ritonavir Sustained Release Tablets Using Quality by Design Approach
Dhaval Patel, Hitesh Patel & Hiren Chaudhary · Journal of Pharmaceutical Research International · 2021
Darunavir is a nonpeptidic inhibitor of protease and is primarily metabolized by cytochrome P450 3A (CYP3A) isoenzymes. It is usually coadministered with low-dose ritonavir (Darunavir/r). Ritonavir is an inhibitor of CYP3A isoenzymes and pharmacologically enhances Darunavir which...
Open access
Research Article
10.9734/jpri/2021/v33i53B33693